CYH Community Health Systems, Inc. Common Stock
关于 Community Health Systems, Inc. Common Stock 公司概况(来自维基百科)
Community Health Systems, Inc. (CHS) is a Fortune 500 company based in Franklin, Tennessee. It was the largest provider of general hospital healthcare services in the United States in terms of number of acute care facilities. In 2014, CHS had around 200 hospitals, but the number had declined to around 85 in 2021.
阅读更多
Community Health Systems, Inc. (CHS) is a Fortune 500 company based in Franklin, Tennessee. It was the largest provider of general hospital healthcare services in the United States in terms of number of acute care facilities. In 2014, CHS had around 200 hospitals, but the number had declined to around 85 in 2021.
In August 2015, the company announced plans to spin off 38 hospitals and its management and consulting subsidiary, Quorum Health Resources, into a new publicly traded company called Quorum Health Corporation. The company completed the spinoff of Quorum Health Corporation on April 29, 2016. Quorum owns or leases hospitals across 16 states, primarily in cities or counties with populations of 50,000 or less. In April 2020 Quorum declared bankruptcy and is no longer trading on the NYSE.
On October 3, 2016, CHS was removed from the S&P Midcap 400 and added to the S&P Smallcap 600. Under CEO Wayne T. Smith, the company's stock has lost over 76% of its value since the year 2000.
Chinese billionaire Tianqiao Chen had a 22.2 percent stake in Community Health Systems in 2017.
History
Founding and early years (1985–2014)
E. Thomas Chaney, former executive of Hospital Affiliates, Inc. and David Steffy and Richard Ragsdale, former executives at Hospital Corporation of America spinoff Republic Health Corporation, formed Community Health Systems in 1985.
The company made its initial public offering in 1991. In 1996, the company was purchased by private equity firm Forstmann Little & Company. Community Health Systems went public again in 2000. In August 2003, the company acquired Southside Regional Medical Center. On October 10, 2015, the 372-bed Grandview Medical Center began operating in Birmingham, Alabama, replacing Trinity Medical Center.
In 2000, Community Health Systems paid $31 million to the United States Department of Justice to settle a review of its billing practices.
In 2007, Community Health Systems purchased Plano, Texas-based Triad Hospitals for $6.8 billion, adding nearly 50 hospitals, hospital management and consulting business Quorum Health Resources, and nearly doubling the size of the company. Among the facilities included in the deal was McKenzie-Willamette Hospital in Springfield, Oregon; Trinity Medical Center in Birmingham, Alabama; and the seven hospitals of Lutheran Health Network in the Ft. Wayne, Indiana region.
In 2010, McKenzie-Willamette's healthcare workers' union, SEIU, Local 49, claimed that workload increases, slashed benefits, and staff reductions had lowered the quality of both patient care and quality of life for employees. The union, in its "Profits Before Community" campaign against the hospital, continues to highlight that profits have tripled while charitable care and employee benefits have steadily decreased since the hospital moved from a non-profit to a for-profit enterprise under CHS.
In 2011, it was accused by Tenet Healthcare of overbilling Medicare in its aggressive admissions policy compared to its peers. It was subpoenaed by Medicare on its aggressive billing to the Medicare systems.
In 2013, Community Health Systems entered into an agreement with Health Management Associates to purchase HMA for about $3.6 billion in cash and stock. The merger was completed in January 2014 and made Community Health Systems the largest for-profit hospital operator at the time, with 206 hospitals in 29 states. The acquisition of HMA brought with it liability for lawsuits and criminal charges of fraudulent claims against Medicare and other federal programs. CHS settled these claims for $262 million in October, 2018.
On August 4, 2014, Community Health Systems paid $95.14 million to the United States Department of Justice to resolve multiple lawsuits "alleging that the company knowingly billed government health care programs for inpatient services that should have been billed as outpatient or observation services". As part of the agreement, Community Health Systems was required to enter into a corporate integrity agreement that required the company to participate in compliance efforts.
It was reported on August 18, 2014, that hackers broke into Community Health System's records system and stole data on 4.5 million patients. These data included names, Social Security numbers, physical addresses, birthdays and telephone numbers. CHS provided all patients whose records were impacted with free identity theft protection.
Recent developments (2015–present)
On February 2, 2015, Community Health Systems was required to pay $75 million to settle allegations "that they made illegal donations to county governments to reap more federal dollars under a now-discontinued matching program". The allegations were brought about by a former CHS employee in a complaint under the False Claims Act.
In October 2015, Community Health Systems paid $13 million to the United States Department of Justice to resolve allegations related to the False Claims Act.
After CHS agreed in 2015 to sell Memorial Hospital of Salem County in New Jersey to Prime Healthcare Foundation, a nonprofit affiliated with Prime Healthcare Services; the sale was approved by New Jersey in early February 2017.
On December 6, 2016, a former CFO of a CHS hospital was awarded $1.9 million in a whistleblower lawsuit he filed after he was terminated for refusing to submit false financial documents.
In January 2017, a settlement between investors and CHS executives for $60 million was reached. The settlement resolved allegations of "breach of fiduciary duty" by CHS executives.
In March 2017, Quorum's board retained outside counsel in relation to whether Community Health Systems had committed fraud with regards to financial projections for Quorum, and whether any of its current management may have been involved in any possible fraud. In June 2017 Quorum said although the investigation did not produce "conclusive evidence" of fraud the projections appeared to be incompetent at best.
In April–July 2017, Community Health Systems rejected overtures from key Lutheran Health Network doctors to facilitate sale of its profitable network in CHS to a third party, after assertions of continual lack of re-investment into the network's facilities and staff by CHS management. After those discussions/accusations became public, several key leaders of the affiliated hospitals, Lutheran and Dupont, and the network were fired or resigned. Key prominent local community leaders Chuck Surack and Tom Kelley resigned from the Lutheran Health Network's and hospitals' advisory boards.
On March 13, 2018, it was reported that the company had hired financial advisory firm Lazard to help address long-term debt.
On August 1, 2018, CHS completed the sale of 425-bed Munroe Regional Medical Center in Ocala, Fla., to Altamonte Springs, Fla.-based Adventist Health System.
On May 22, 2019, AdventHealth announced they had signed definitive agreements to purchase 193-bed Heart of Florida Regional Medical Center in Davenport, Florida, and 160-bed Lake Wales Medical Center in Lake Wales, Florida, from affiliates of CHS.
In December 2019, CHS announced that subsidiaries of the company have completed the sale of three Virginia hospitals – Southside Regional Medical Center in Petersburg, Southampton Memorial Hospital in Franklin, and Southern Virginia Regional Medical Center in Emporia, effective on January 1, 2020.
On April 27, 2020, CHS announced that an affiliate of the company has signed a definitive agreement to sell its majority ownership interest in 84‑bed St. Cloud Regional Medical Center and its associated healthcare operations in St. Cloud, Florida, to a subsidiary of Orlando Health. Orlando Health currently holds minority ownership interest in St. Cloud and will purchase the remaining interest through this transaction.
On September 30, 2020, CHS announced that an affiliate of the company has completed the sale of 480-bed Bayfront Health St. Petersburg and its associated assets to a subsidiary of Orlando Health.
In its annual Form 10-K filed in 2019, it identified Florida, Texas and Indiana as areas of geographic concentration.
In 2014, CHS had around 200 hospitals, but the number had declined to around 85 in 2021.
From March 2020 to May 2021, during the COVID-19 pandemic, CHS filed more than 19,000 lawsuits against individuals for not being able to pay off their medical debt (some from hospitals it no longer owned) even as the company collected over $700 million in Covid relief funds from the federal government. Many of these lawsuits were against people who could not pay the legal fees to challenge CHS in court. (Due to the fact that these are civil suits and not criminal suits, the defendants do not receive a state-appointed lawyer.) In 2020, CHS posted its most profitable year in at least a decade.
Predatory liens practices
Lawsuits have been filed against CHS hospitals for alleged predatory liens practices where hospitals file for liens rather than bill individuals' health insurers, resulting in massive fees for patients.
来源:维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
CYH 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
CYH 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜?
盈利能力 毛利率、营业利润率和净利率;股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
财务健康 债务、流动性、偿付能力 — 资产负债表强度
成长 营收、每股收益 (EPS) 和净利润增长:同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
资本效率 资产周转率、库存周转率、应收账款周转率
股息 收益率、派息率、股息历史、5年CAGR
| 除息日 | 金额 |
|---|---|
| 2012年12月13日 | $0.2066 |
CYH 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
- 强烈买入 1 6.2%
- 买入 1 6.2%
- 持有 6 37.5%
- 卖出 7 43.8%
- 强烈卖出 1 6.2%
12个月价格目标
7 位分析师 · 2026-08-13收益历史 每股收益实际值 vs 预估值,惊喜%,达标率,下次财报日期
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-0.19 | $-0.06 | -0.13% |
| 2026年3月31日 | $-0.48 | $-0.10 | -0.38% |
| 2025年12月31日 | $-0.01 | $-0.10 | 0.10% |
| 2025年9月30日 | $1.27 | $-0.25 | 1.5% |
| 2025年6月30日 | $-0.05 | $-0.11 | 0.06% |
| 2025年3月31日 | $-0.03 | $-0.08 | 0.05% |
同行比较(GICS 子行业) 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| CYH | $433M | 0.8 | -1.2% | 4.1% | -30.8% | — |
| SNDA | $612M | -7.7 | 25.2% | -18.6% | -197.2% | — |
| ARDT | $1.26B | 9.2 | 6.0% | 2.1% | 11.2% | — |
| NUTX | $1.17B | 15.7 | 82.4% | 8.1% | 30.6% | 50.8% |
| USPH | — | 55.0 | 16.3% | 5.1% | 8.2% | 19.2% |
| JYNT | $123M | 45.9 | 5.2% | 5.3% | 16.3% | — |
| HCA | $104.86B | 16.5 | 7.1% | 9.0% | -159.1% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 13
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.48B | $12.63B | $12.49B | $12.21B | $12.37B | $11.79B | $13.21B | $14.15B | $15.35B | $18.44B | |
| Cost of Revenue | $1.86B | $1.95B | $1.99B | $1.98B | $2.04B | $1.96B | $2.15B | $2.35B | $2.67B | $3.01B | |
| Operating Expenses | $11.00B | $12.09B | $11.53B | $11.39B | $10.97B | $10.66B | $12.56B | $13.95B | $17.23B | $19.30B | |
| Operating Income | $1.49B | $542M | $957M | $821M | $1.40B | $1.13B | $650M | $208M | $-1.88B | $-860M | |
| Interest Income | $2M | $3M | $2M | $2M | $3M | $3M | $3M | $7M | $11M | $14M | |
| Pretax Income | $724M | $-283M | $207M | $349M | $499M | $422M | $-430M | $-715M | $-2.83B | $-1.72B | |
| Income Tax | $48M | $79M | $191M | $170M | $131M | $-185M | $160M | $-11M | $-449M | $-104M | |
| Net Income | $509M | $-516M | $-133M | $46M | $230M | $511M | $-675M | $-788M | $-2.46B | $-1.72B | |
| EPS (Basic) | $3.81 | $-3.90 | $-1.02 | $0.35 | $1.82 | $4.43 | $-5.93 | $-6.99 | $-22.00 | $-15.54 | |
| EPS (Diluted) | $3.77 | $-3.90 | $-1.02 | $0.35 | $1.76 | $4.39 | $-5.93 | $-6.99 | $-22.00 | $-15.54 | |
| Shares (Basic) | 133,564,227 | 132,101,768 | 130,445,677 | 128,808,387 | 126,754,852 | 115,491,022 | 113,739,046 | 112,728,274 | 111,769,821 | 110,730,971 | |
| Shares (Diluted) | 135,012,240 | 132,101,768 | 130,445,677 | 130,060,319 | 130,597,410 | 116,544,561 | 113,739,046 | 112,728,274 | 111,769,821 | 110,730,971 | |
| EBITDA | $1.49B | $542M | $957M | $821M | $1.40B | $1.13B | $1.26B | $908M | $-1.02B | $240M |
资产负债表 26
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $260M | $37M | $38M | $118M | $507M | $1.68B | $216M | $196M | $563M | $238M | |
| Receivables | $2.08B | $2.29B | $2.23B | $2.04B | $2.06B | $1.93B | $2.26B | $2.35B | $2.38B | $3.18B | |
| Other Current Assets | $381M | $358M | $275M | $235M | $269M | $338M | $358M | $400M | $462M | $568M | |
| Current Assets | $3.23B | $3.30B | $3.21B | $3.08B | $3.48B | $4.51B | $3.43B | $3.55B | $4.07B | $4.67B | |
| PP&E (Net) | $4.50B | $4.78B | $5.21B | $5.37B | $5.55B | $5.32B | $5.61B | $6.14B | $7.05B | $8.15B | |
| PP&E (Gross) | $8.91B | $9.16B | $9.51B | $9.64B | $9.76B | $9.35B | $9.65B | $10.30B | $11.50B | $12.42B | |
| Accum. Depreciation | $4.41B | $4.38B | $4.30B | $4.27B | $4.20B | $4.03B | $4.04B | $4.16B | $4.45B | $4.27B | |
| Goodwill | $3.32B | $3.79B | $3.96B | $4.17B | $4.22B | $4.22B | $4.33B | $4.56B | $4.72B | $6.52B | |
| Intangibles | $7M | $15M | $20M | $2M | · | · | · | · | $10M | $14M | |
| Other Non-current Assets | $2.10B | $2.17B | $2.05B | $2.01B | $1.91B | $1.90B | $2.21B | $1.54B | $1.54B | $2.59B | |
| Total Assets | $13.20B | $14.05B | $14.46B | $14.67B | $15.22B | $16.01B | $15.61B | $15.86B | $17.45B | $21.94B | |
| Accounts Payable | $842M | $913M | $912M | $773M | $830M | $783M | $811M | $887M | $967M | $995M | |
| Accrued Liabilities | · | · | · | · | · | · | $1.13B | $1.09B | $1.13B | $1.23B | |
| Current Liabilities | $2.21B | $2.35B | $2.14B | $2.19B | $2.36B | $2.81B | $2.28B | $2.39B | $2.36B | $2.89B | |
| Capital Leases | $537M | $535M | $563M | $605M | $535M | $524M | $487M | $84M | $287M | $302M | |
| Deferred Tax | $25M | $231M | $369M | $354M | $192M | $29M | $200M | $26M | $19M | $411M | |
| Other Non-current Liabilities | $891M | $828M | $739M | $644M | $827M | $1.60B | $894M | $1.01B | $1.36B | $1.57B | |
| Total Liabilities | $14.04B | $15.37B | $15.28B | $15.40B | $16.03B | $17.06B | $17.25B | $16.82B | $17.61B | $19.66B | |
| Long-term Debt | $10.40B | $11.45B | $11.49B | $11.63B | $12.14B | $12.22B | $13.40B | $13.60B | $13.91B | $15.24B | |
| Total Debt | $10.38B | $11.43B | $11.47B | $11.61B | $12.11B | $12.09B | $13.38B | · | · | · | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| Retained Earnings | $-3.57B | $-4.08B | $-3.56B | $-3.43B | $-3.48B | $-3.71B | $-4.22B | $-3.54B | $-2.76B | $-299M | |
| AOCI | $-9M | $-10M | $-14M | $-21M | $-14M | $-13M | $-9M | $-10M | $-21M | $-62M | |
| Stockholders' Equity | $-1.39B | $-1.91B | $-1.39B | $-1.37B | $-1.37B | $-1.62B | $-2.22B | $-1.53B | $-767M | $1.61B | |
| Liabilities + Equity | $13.20B | $14.05B | $14.46B | $14.67B | $15.22B | $16.01B | $15.61B | $15.86B | $17.45B | $21.94B | |
| Shares Outstanding | 138,626,917 | 138,919,641 | 136,774,911 | 134,703,717 | 132,146,282 | 129,612,117 | 117,822,631 | 116,248,376 | 114,651,004 | 113,876,580 |
现金流 13
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $426M | $486M | $505M | $534M | $540M | $558M | $608M | $700M | $861M | $1.10B | |
| Stock-based Comp | $11M | $17M | $22M | $20M | $25M | $13M | $10M | $13M | $24M | $46M | |
| Deferred Tax | $-243M | $-116M | $35M | $165M | $171M | $-187M | $203M | $-3M | $-454M | $-116M | |
| Restructuring | · | · | · | · | $3M | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | $239M | $352M | $2.80B | $1.83B | |
| Operating Cash Flow | $543M | $480M | $210M | $300M | $-131M | $2.18B | $385M | $274M | $773M | $1.14B | |
| CapEx | $335M | $360M | $467M | $415M | $469M | $440M | $438M | $527M | $564M | $744M | |
| Investing Cash Flow | $847M | $-275M | $-26M | $-259M | $-524M | $177M | $-2M | $-245M | $1.07B | $630M | |
| Net Debt Issued | $-6.52B | $-5.06B | $-4.32B | $-2.36B | $-4.43B | $-5.49B | $-3.56B | $-2.03B | $-5.39B | $-6.71B | |
| Financing Cash Flow | $-1.17B | $-206M | $-264M | $-430M | $-514M | $-895M | $-363M | $-396M | $-1.52B | $-1.71B | |
| Net Change in Cash | $223M | $-1M | $-80M | $-389M | $-1.17B | $1.46B | $20M | $-367M | $325M | $54M | |
| Taxes Paid | $249M | $171M | $91M | $-6M | $-4M | $-2M | $3M | $19M | $-4M | $16M | |
| Free Cash Flow | $208M | $120M | $-257M | $-115M | $-600M | $1.74B | $-53M | $-253M | $209M | $393M |
盈利能力 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.9% | 4.3% | 7.7% | 6.7% | 11.3% | 9.6% | 4.9% | 1.5% | · | · | |
| Net Margin | 4.1% | -4.1% | -1.1% | 0.38% | 1.9% | 4.3% | -5.1% | -5.6% | · | · | |
| Pretax Margin | 5.8% | -2.2% | 1.7% | 2.9% | 4.0% | 3.6% | -3.3% | -5.1% | · | · | |
| EBITDA Margin | 11.9% | 4.3% | 7.7% | 6.7% | 11.3% | 9.6% | 9.5% | 6.4% | · | · | |
| ROA | 3.7% | -3.6% | -0.91% | 0.31% | 1.5% | 3.2% | -4.3% | -4.7% | -12.5% | -7.1% | |
| ROE | -30.8% | 31.2% | 9.6% | -3.4% | -15.3% | -26.6% | 36.0% | 68.5% | -580.0% | -61.1% | |
| ROIC | 15.5% | 7.3% | 0.73% | 4.1% | 9.6% | 15.5% | 8.0% | -13.3% | 206.0% | -50.0% |
流动性与偿付能力 4
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.5 | 1.4 | 1.5 | 1.4 | 1.5 | 1.6 | 1.5 | 1.5 | 1.7 | 1.6 | |
| Quick Ratio | 1.1 | 1.0 | 1.1 | 1.0 | 1.1 | 1.3 | 1.1 | 1.1 | 1.3 | 1.2 | |
| Debt / Equity | -7.4 | -6.0 | -8.2 | -8.5 | -8.8 | -7.4 | -6.0 | · | · | · | |
| LT Debt / Equity | -7.4 | -6.0 | -8.2 | -8.5 | -8.8 | -7.4 | -6.0 | · | · | · |
效率 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.9 | 0.9 | 0.9 | 0.8 | 0.8 | 0.7 | 0.8 | 0.8 | · | · | |
| Receivables Turnover | 5.7 | 5.6 | 5.8 | 6.0 | 6.2 | 5.6 | 5.7 | 6.0 | · | · |
增长率 9
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -1.2% | 1.1% | 2.3% | -1.3% | 4.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 0.74% | 0.71% | 1.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 1.1% | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | · | · | -80.1% | -59.9% | · | · | · | · | · | |
| EPS CAGR 3Y | 120.8% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.0% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | · | · | -80.0% | -55.0% | · | · | · | · | · | |
| Net Income CAGR 3Y | 122.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -0.08% | · | · | · | · | · | · | · | · | · |
估值 (TTM) 13
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $12.48B | $12.63B | $12.49B | $12.21B | $12.37B | $11.79B | $13.21B | $14.15B | $15.35B | $18.44B | |
| Net Income TTM | $509M | $-516M | $-133M | $46M | $230M | $511M | $-675M | $-788M | $-2.46B | $-1.72B | |
| Market Cap | $433M | $415M | $428M | $582M | $1.76B | $963M | $342M | $328M | $488M | $637M | |
| Enterprise Value | $10.55B | $11.81B | $11.86B | $12.08B | $13.36B | $11.38B | $13.51B | · | · | · | |
| P/E | 0.8 | -0.8 | -3.1 | 12.3 | 7.6 | 1.7 | -0.5 | -0.4 | -0.2 | -0.4 | |
| P/S | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | |
| P/B | -0.3 | -0.2 | -0.3 | -0.4 | -1.3 | -0.6 | -0.2 | -0.2 | -0.6 | 0.4 | |
| P / Cash Flow | 0.8 | 0.9 | 2.0 | 1.9 | -13.4 | 0.4 | 0.9 | 1.2 | 0.6 | 0.6 | |
| P / FCF | 2.1 | 3.5 | -1.7 | -5.1 | -2.9 | 0.6 | -6.4 | -1.3 | 2.3 | 1.6 | |
| EV / EBITDA | 7.1 | 21.8 | 12.4 | 14.7 | 9.5 | 10.1 | 10.7 | · | · | · | |
| EV / FCF | 50.7 | 98.4 | -46.1 | -105.0 | -22.3 | 6.5 | -254.9 | · | · | · | |
| EV / Revenue | 0.8 | 0.9 | 0.9 | 1.0 | 1.1 | 1.0 | 1.0 | · | · | · | |
| Earnings Yield | 120.8% | -130.4% | -32.6% | 8.1% | 13.2% | 59.1% | -204.5% | -247.9% | -516.4% | -278.0% |
损益表 13
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.83B | $2.96B | $3.11B | $3.09B | $3.13B | $3.16B | $3.26B | $3.09B | $3.14B | $3.14B | $3.18B | $3.09B | $3.12B | $3.11B | $3.14B | $3.02B | |
| Cost of Revenue | $401M | $441M | $446M | $460M | $469M | $489M | $507M | $469M | $483M | $487M | $493M | $489M | $504M | $507M | $497M | $492M | |
| Operating Expenses | $2.44B | $2.68B | $2.66B | $2.84B | $2.62B | $2.88B | $2.99B | $3.29B | $2.90B | $2.91B | $2.85B | $2.91B | $2.87B | $2.90B | $2.91B | $2.82B | |
| Operating Income | $389M | $281M | $449M | $243M | $512M | $284M | $278M | $-205M | $238M | $231M | $328M | $173M | $246M | $210M | $228M | $204M | |
| Interest Income | $1M | $1M | $0 | $1M | $1M | · | $1M | $1M | · | · | · | · | · | · | · | · | |
| Pretax Income | $180M | $64M | $221M | $-2M | $438M | $67M | $64M | $-419M | $50M | $22M | $194M | $-33M | $40M | $6M | $324M | $70M | |
| Income Tax | $76M | $89M | $61M | $-173M | $118M | $42M | $91M | $-64M | $24M | $28M | $108M | $19M | $38M | $26M | $-123M | $70M | |
| Net Income | $70M | $-58M | $110M | $130M | $282M | $-13M | $-71M | $-391M | $-13M | $-41M | $47M | $-91M | $-38M | $-51M | $415M | $-42M | |
| EPS (Basic) | $0.51 | $-0.43 | $0.83 | $0.97 | $2.11 | $-0.10 | $-0.53 | $-2.95 | $-0.10 | $-0.32 | $0.36 | $-0.69 | $-0.29 | $-0.40 | $3.20 | $-0.32 | |
| EPS (Diluted) | $0.51 | $-0.43 | $0.82 | $0.96 | $2.09 | $-0.10 | $-0.53 | $-2.95 | $-0.10 | $-0.32 | $0.36 | $-0.69 | $-0.29 | $-0.40 | $3.20 | $-0.32 | |
| Shares (Basic) | 135,494,789 | 134,417,158 | -266,863,732 | 133,787,535 | 133,763,733 | 132,876,691 | -263,891,006 | 132,376,226 | 132,344,504 | 131,272,044 | -260,601,819 | 130,698,907 | 130,659,672 | 129,688,917 | -257,247,066 | 129,141,673 | |
| Shares (Diluted) | 136,505,102 | 134,417,158 | -267,935,024 | 135,187,592 | 134,882,981 | 132,876,691 | -263,891,006 | 132,376,226 | 132,344,504 | 131,272,044 | -260,601,819 | 130,698,907 | 130,659,672 | 129,688,917 | -255,995,134 | 129,141,673 | |
| EBITDA | $389M | $281M | · | $243M | $512M | $284M | · | $-205M | $238M | $231M | · | $173M | $246M | $210M | · | $204M |
资产负债表 25
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $149M | $712M | $260M | $123M | $456M | $431M | $37M | $33M | $39M | $48M | · | $91M | $118M | $144M | · | $300M | |
| Receivables | $2.14B | $2.14B | $2.08B | $2.16B | $2.26B | $2.33B | $2.29B | $2.04B | $2.19B | $2.19B | · | $2.16B | $2.04B | $2.04B | · | $1.97B | |
| Other Current Assets | $308M | $421M | $381M | $325M | $351M | $61M | $358M | $402M | $292M | $307M | · | $325M | $339M | $227M | · | $301M | |
| Current Assets | $3.08B | $3.77B | $3.23B | $3.20B | $3.66B | $3.41B | $3.30B | $3.11B | $3.20B | $3.17B | · | $3.25B | $3.19B | $3.11B | · | $3.27B | |
| PP&E (Net) | $4.18B | $4.20B | $4.50B | $4.62B | $4.66B | $4.74B | $4.78B | $4.96B | $5.22B | $5.22B | · | $5.16B | $5.25B | $5.25B | · | $5.45B | |
| PP&E (Gross) | $8.04B | $8.09B | $8.91B | $9.06B | $9.02B | $9.20B | $9.16B | $9.09B | $9.59B | $9.61B | · | $9.37B | $9.53B | $9.56B | · | $9.73B | |
| Accum. Depreciation | $3.86B | $3.89B | $4.41B | $4.44B | $4.37B | $4.46B | $4.38B | $4.13B | $4.37B | $4.39B | · | $4.21B | $4.28B | $4.30B | · | $4.28B | |
| Goodwill | $3.23B | $3.13B | $3.32B | $3.54B | $3.60B | $3.79B | $3.79B | $3.94B | $3.97B | $3.96B | $3.96B | $3.94B | $4.05B | $4.05B | $4.17B | $4.20B | |
| Intangibles | · | · | $7M | · | · | · | $15M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $1.65B | $2.05B | $2.10B | $1.81B | $1.71B | $1.94B | $2.17B | $1.86B | $1.99B | $2.04B | · | $2.27B | $2.10B | $2.15B | · | $1.94B | |
| Total Assets | $12.18B | $13.18B | $13.20B | $13.24B | $13.64B | $13.89B | $14.05B | $13.90B | $14.41B | $14.42B | · | $14.67B | $14.65B | $14.62B | · | $14.91B | |
| Accounts Payable | $713M | $790M | $842M | $894M | $970M | $974M | $913M | $842M | $896M | $941M | · | $837M | $736M | $712M | · | $820M | |
| Current Liabilities | $2.02B | $2.57B | $2.21B | $2.18B | $2.29B | $2.37B | $2.35B | $2.13B | $2.17B | $2.14B | · | $2.15B | $2.08B | $2.13B | · | $2.38B | |
| Capital Leases | $527M | $504M | $537M | $527M | $514M | $535M | $535M | $528M | $542M | $546M | · | $560M | $580M | $588M | · | $563M | |
| Deferred Tax | $25M | $25M | $25M | $30M | $240M | $205M | $231M | $239M | $351M | $354M | · | $344M | $362M | $351M | · | $477M | |
| Other Non-current Liabilities | $901M | $922M | $891M | $866M | $850M | $806M | $828M | $815M | $721M | $726M | · | $694M | $722M | $647M | · | $726M | |
| Total Liabilities | $13.02B | $14.14B | $14.04B | $14.19B | $14.74B | $15.22B | $15.37B | $15.18B | $15.29B | $15.29B | · | $15.57B | $15.47B | $15.41B | · | $16.09B | |
| Long-term Debt | · | · | $10.40B | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $9.55B | $10.13B | · | $10.59B | $10.84B | $11.30B | · | $11.47B | $11.50B | $11.53B | · | $11.82B | $11.73B | $11.70B | · | $11.94B | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Retained Earnings | $-3.56B | $-3.63B | $-3.57B | $-3.68B | $-3.81B | $-4.09B | $-4.08B | $-4.01B | $-3.62B | $-3.60B | · | $-3.61B | $-3.52B | $-3.48B | · | $-3.85B | |
| AOCI | $-11M | $-10M | $-9M | $-5M | $-5M | $-7M | $-10M | $-8M | $-13M | $-16M | · | $-23M | $-19M | $-18M | $-21M | $-33M | |
| Stockholders' Equity | $-1.39B | $-1.45B | $-1.39B | $-1.50B | $-1.63B | $-1.92B | $-1.91B | $-1.82B | $-1.44B | $-1.43B | · | $-1.46B | $-1.49B | $-1.45B | · | $-1.79B | |
| Liabilities + Equity | $12.18B | $13.18B | $13.20B | $13.24B | $13.64B | $13.89B | $14.05B | $13.90B | $14.41B | $14.42B | · | $14.67B | $14.65B | $14.62B | · | $14.91B | |
| Shares Outstanding | 141,010,284 | 140,916,712 | 138,626,917 | 140,119,616 | 140,119,616 | 140,302,924 | 138,919,641 | 138,936,058 | 138,960,194 | 138,966,388 | · | 136,772,094 | 136,802,806 | 136,749,427 | · | 134,698,067 |
现金流 10
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $108M | $114M | $108M | $108M | $105M | $105M | $129M | $117M | $125M | $115M | $121M | $128M | $124M | $132M | $136M | $137M | |
| Stock-based Comp | $2M | $3M | $5M | $-1M | $3M | $4M | $5M | $4M | $2M | $6M | $6M | $6M | $4M | $6M | $6M | $6M | |
| Operating Cash Flow | $88M | $-297M | $266M | $69M | $88M | $120M | $216M | $67M | $101M | $96M | $90M | $29M | $86M | $5M | $9M | $137M | |
| CapEx | $76M | $76M | $94M | $65M | $91M | $85M | $109M | $70M | $88M | $93M | $110M | $130M | $105M | $122M | $131M | $93M | |
| Investing Cash Flow | $-23M | $1.02B | $142M | $-81M | $342M | $444M | $-143M | $75M | $-108M | $-99M | $180M | $-101M | $-86M | $-19M | $-52M | $30M | |
| Net Debt Issued | · | $-351M | · | · | · | $-1.09B | · | · | · | $-885M | · | · | · | $-757M | · | · | |
| Financing Cash Flow | $-628M | $-274M | $-271M | $-321M | $-405M | $-170M | $-69M | $-148M | $-2M | $13M | $-323M | $45M | $-26M | $40M | $-139M | $-213M | |
| Net Change in Cash | $-563M | $452M | $137M | $-333M | $25M | $394M | $4M | $-6M | $-9M | $10M | $-53M | · | · | $26M | $-182M | $-46M | |
| Taxes Paid | $61M | $0 | $441M | $-91M | $181M | $80M | $303M | $-48M | $-84M | $0 | $152M | $-24M | $-37M | · | $0 | $0 | |
| Free Cash Flow | · | $-373M | · | · | · | $35M | · | · | · | $3M | · | · | · | $-117M | · | · |
盈利能力 7
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.8% | 9.5% | · | 7.9% | 16.3% | 9.0% | · | -6.6% | 7.6% | 7.4% | · | 5.6% | 7.9% | 6.8% | · | 6.7% | |
| Net Margin | 2.5% | -2.0% | · | 4.2% | 9.0% | -0.41% | · | -12.7% | -0.41% | -1.3% | · | -2.9% | -1.2% | -1.6% | · | -1.4% | |
| Pretax Margin | 6.4% | 2.2% | · | -0.06% | 14.0% | 2.1% | · | -13.6% | 1.6% | 0.70% | · | -1.1% | 1.3% | 0.19% | · | 2.3% | |
| EBITDA Margin | 13.8% | 9.5% | · | 7.9% | 16.3% | 9.0% | · | -6.6% | 7.6% | 7.4% | · | 5.6% | 7.9% | 6.8% | · | 6.7% | |
| ROA | 0.54% | -0.43% | · | 0.96% | 2.0% | -0.09% | · | -2.7% | -0.09% | -0.28% | · | -0.62% | -0.26% | -0.34% | · | -0.27% | |
| ROE | -4.6% | 3.4% | · | -7.8% | -18.4% | 0.78% | · | 23.8% | 0.89% | 2.9% | · | 5.6% | 2.4% | 3.6% | · | 2.5% | |
| ROIC | 2.8% | -1.3% | · | -228.6% | 4.1% | 1.1% | · | -1.8% | 1.2% | -0.62% | · | 2.6% | 0.12% | -6.8% | · | 0.00% |
流动性与偿付能力 4
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.5 | 1.5 | · | 1.5 | 1.6 | 1.4 | · | 1.5 | 1.5 | 1.5 | · | 1.5 | 1.5 | 1.5 | · | 1.4 | |
| Quick Ratio | 1.1 | 1.1 | · | 1.0 | 1.2 | 1.2 | · | 1.0 | 1.0 | 1.0 | · | 1.0 | 1.0 | 1.0 | · | 1.0 | |
| Debt / Equity | -6.9 | -7.0 | · | -7.0 | -6.6 | -5.9 | · | -6.3 | -8.0 | -8.1 | · | -8.1 | -7.9 | -8.1 | · | -6.7 | |
| LT Debt / Equity | -6.9 | -7.0 | · | -7.0 | -6.6 | -5.9 | · | -6.3 | -8.0 | -8.1 | · | -8.1 | -7.9 | -8.1 | · | -6.7 |
效率 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.5 | 1.5 | · | 1.5 | 1.5 | 1.5 | · | 1.5 |
估值 (TTM) 13
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $12.01B | $12.34B | · | $12.47B | $12.52B | $12.53B | · | $12.46B | $12.48B | $12.45B | · | $12.33B | $12.18B | $12.18B | · | $12.19B | |
| Net Income TTM | $424M | $341M | · | $8M | $-135M | $-458M | · | $-536M | $-183M | $-221M | · | $-222M | $-457M | $-420M | · | $-258M | |
| Market Cap | $471M | $414M | · | $450M | $476M | $379M | · | $843M | $467M | $486M | · | $397M | $602M | $670M | · | $290M | |
| Enterprise Value | $9.87B | $9.83B | · | $10.92B | $10.86B | $11.25B | · | $12.28B | $11.93B | $11.97B | · | $12.13B | $12.21B | $12.22B | · | $11.93B | |
| P/E | 1.1 | 1.2 | · | · | -3.2 | -0.8 | · | -1.5 | -2.4 | -2.1 | · | -1.7 | -1.2 | -1.5 | · | -1.1 | |
| P/S | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.1 | · | 0.0 | |
| P/B | -0.3 | -0.3 | · | -0.3 | -0.3 | -0.2 | · | -0.5 | -0.3 | -0.3 | · | -0.3 | -0.4 | -0.5 | · | -0.2 | |
| P / Cash Flow | · | -1.4 | · | · | · | 3.2 | · | · | · | 5.1 | · | · | · | 134.0 | · | · | |
| P / FCF | · | -1.1 | · | · | · | 10.8 | · | · | · | 162.1 | · | · | · | -5.7 | · | · | |
| EV / EBITDA | 25.4 | 35.0 | · | 44.9 | 21.2 | 39.6 | · | -59.9 | 50.1 | 51.8 | · | 70.1 | 49.6 | 58.2 | · | 58.5 | |
| EV / FCF | · | -26.4 | · | · | · | 321.5 | · | · | · | 3990.5 | · | · | · | -104.5 | · | · | |
| EV / Revenue | 0.8 | 0.8 | · | 0.9 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.0 | · | 1.0 | 1.0 | 1.0 | · | 1.0 | |
| Earnings Yield | 93.7% | 85.7% | · | 0.00% | -31.2% | -128.5% | · | -66.9% | -41.7% | -48.6% | · | -58.6% | -80.2% | -66.3% | · | -93.0% |
财务报表 损益表、资产负债表、现金流量表 — 年度,近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $12.48B | $12.63B | $12.49B | $12.21B | $12.37B |
| 营业利润率 % | 11.9% | 4.3% | 7.7% | 6.7% | 11.3% |
| 净收入 | $509M | $-516M | $-133M | $46M | $230M |
| 稀释后每股收益 (EPS) | $3.77 | $-3.90 | $-1.02 | $0.35 | $1.76 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 负债/股东权益比率 | -7.4 | -6.0 | -8.2 | -8.5 | -8.8 |
| 流动比率 | 1.5 | 1.4 | 1.5 | 1.4 | 1.5 |
| 速动比率 | 1.1 | 1.0 | 1.1 | 1.0 | 1.1 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $208M | $120M | $-257M | $-115M | $-600M |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存,并会跟随您浏览所有股票。
机构持有人 (13F) 201 家申报者 · $341.1M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸;单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存,而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 37 (+19 与上一季度对比) | 24 (+4 与上一季度对比) | 65 (+4 与上一季度对比) | 49 (-12 与上一季度对比) | +15.7M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天,外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过,优先显示最近一个已完整报告的季度对。
公司内部人士 57 位内幕人士 · 29 位高管 · 23 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Kevin J Hammons | CEO | 2026年3月1日 A | 895545 | 0 | 0 | $0 |
| Tim Hingtgen | CEO | 2025年3月1日 A | 1388781 | 0 | 0 | $0 |
| Jason K Johnson | EVP & CFO | 2026年3月1日 A | 268439 | 0 | 0 | $0 |
| Thomas J Aaron | EVP and CFO | 2019年12月7日 F | 241515 | 0 | 0 | $0 |
| Larry W Cash | President and CFO | 2017年3月1日 A | 568152 | 0 | 0 | $0 |
| Miguel S Benet | President and CMO | 2025年3月1日 D | 47635 | 0 | 0 | $0 |
| Austen D Mason | Regional President | 2025年3月1日 A | 142500 | 0 | 0 | $0 |
| Mark B Medley | Regional President | 2025年3月1日 A | 128637 | 0 | 0 | $0 |
| Chad A Campbell | Regional President | 2025年3月1日 A | 136815 | 0 | 0 | $0 |
| Charles J Cova | Regional President | 2024年3月1日 A | 58701 | 0 | 0 | $0 |
| Lynn T Simon | President and CMO | 2024年3月1日 A | 482657 | 0 | 0 | $0 |
| Beryl Ramsey | Division President | 2019年3月1日 A | 62969 | 0 | 0 | $0 |
| Patton Paul Smith | Division President | 2019年3月1日 F | 119017 | 0 | 0 | $0 |
| Iii John W Mcclellan | Division President | 2017年3月1日 A | 41242 | 0 | 0 | $0 |
| Robert O Horrar | Division President | 2017年3月1日 A | 68649 | 0 | 0 | $0 |
| Martin Bonick | Division President | 2017年3月1日 A | 100458 | 0 | 0 | $0 |
| Michael T Portacci | Division President | 2017年3月1日 A | 110156 | 0 | 0 | $0 |
| Thomas Daniel Miller | Division President | 2016年3月1日 A | 112107 | 0 | 0 | $0 |
| David Lewis Miller | President and COO | 2016年3月1日 A | 440840 | 0 | 0 | $0 |
| William S Hussey | Division President | 2015年10月28日 M | 121568 | 0 | 0 | $0 |
| Martin Dewayne Smith | Division President | 2015年6月3日 M | 94111 | 0 | 0 | $0 |
| Gary D Newsome | Division President - Group Ops | 2008年8月25日 M | 118286 | 0 | 0 | $0 |
| David V. Rice | EVP-Clinical Operations & CMO | 2026年6月1日 A | 30000 | 0 | 0 | $0 |
| Phillip A. Posey | SVP & CAO | 2026年3月1日 A | 51736 | 0 | 0 | $0 |
| Justin D Pitt | Pres,Chief Legal&Admin Officer | 2026年3月1日 A | 287750 | 0 | 0 | $0 |
| Kevin A Stockton | EVP, Operations & Development | 2026年3月1日 A | 208290 | 0 | 0 | $0 |
| Rachel A Seifert | Executive VP and Secretary | 2017年3月1日 F | 243065 | 0 | 0 | $0 |
| Mark T Buford | SVP/Chief Accounting Officer | 2012年2月25日 F | 78379 | 0 | 0 | $0 |
| Martin G Schweinhart | Senior Vice President | 2006年3月1日 A | 40354 | 0 | 0 | $0 |
| Ranga K Krishnan | 董事 | 2026年6月30日 M | 170023 | 0 | 0 | $0 |
| Fawn D Lopez | 董事 | 2026年3月1日 A | — | 0 | 0 | $0 |
| Ronald L Burgess JR | 董事 | 2026年3月1日 A | — | 0 | 0 | $0 |
| Susan W Brooks | 董事 | 2026年3月1日 A | 108695 | 0 | 0 | $0 |
| Hubert James Williams | 董事 | 2026年3月1日 A | 211863 | 0 | 0 | $0 |
| Joseph Arthur Hastings | 董事 | 2026年3月1日 A | 0 | 0 | 0 | $0 |
| Elizabeth T Hirsch | 董事 | 2026年3月1日 A | 162059 | 0 | 0 | $0 |
| James S. Ely III | 董事 | 2026年3月1日 A | 412876 | 0 | 0 | $0 |
| William Norris Jennings | 董事 | 2026年3月1日 A | 78468 | 0 | 0 | $0 |
| John A Fry | 董事 | 2026年3月1日 A | 268966 | 0 | 0 | $0 |
| John A Clerico | 董事 | 2026年3月1日 A | 368763 | 0 | 0 | $0 |
| Michael Dinkins | 董事 | 2026年3月1日 A | 225882 | 0 | 0 | $0 |
| Wayne T Smith | 董事 | 2026年3月1日 A | 5217579 | 0 | 0 | $0 |
| Julia B North | 董事 | 2021年3月1日 A | 162056 | 0 | 0 | $0 |
| Mitchell H Watson JR | 董事 | 2017年5月16日 M | 22594 | 0 | 0 | $0 |
| Harvey Klein MD | 董事 | 2010年3月15日 M | 10383 | 0 | 0 | $0 |
| Dale F Frey | 董事 | 2008年3月31日 A | 20000 | 0 | 0 | $0 |
| Thomas H Lister | 董事 | 2004年9月21日 S | 0 | 0 | 0 | $0 |
| Thodore Forstmann | 董事 | 2004年9月21日 S | 0 | 0 | 0 | $0 |
| Sandra Horbach | 董事 | 2004年9月21日 S | 0 | 0 | 0 | $0 |
| Robert J Dole | 董事 | 2004年5月6日 S | 0 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士;净额=仅公开市场买卖
激进投资者及 5%+ 股东 1 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权,意图影响发行人(激进股东持股、董事会活动、并购)。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Tianqiao Chen, Shanda Media Limited, Shanda Global Investment Limited, Shanda Global Capital Limited, Shanda Asset Management Holdings Limited ×10 申报 | 2021年3月11日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 36 只交易所交易基金持有
权重仅反映直接股权持仓(N-PORT);杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| BSJR · Invesco Exchange-Traded Self-Inde... | 2.68% | 21287000 | 2026年8月8日 | 每日 |
| EBIT · Harbor ETF Trust | 0.48% | 19323 NS | 2026年4月30日 | N-PORT |
| VGHY · VANGUARD FIXED INCOME SECURITIES ... | 0.35% | 1058000 PA | 2026年8月8日 | 每日 |
| DFVE · DoubleLine ETF Trust | 0.20% | 18550 NS | 2026年3月31日 | N-PORT |
| IWC · iShares Trust | 0.09% | 441586 SH | 2026年8月8日 | 每日 |
| IHF · iShares Trust | 0.06% | 232511 SH | 2026年8月8日 | 每日 |
| GSSC · Goldman Sachs ETF Trust | 0.04% | 132595 NS | 2026年5月31日 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.03% | 113109 SH | 2026年8月8日 | 每日 |
| NEAR · iShares U.S. ETF Trust | 0.03% | 1304000 SH | 2026年8月8日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.03% | 253747 SH | 2026年8月8日 | 每日 |
| IWN · iShares Trust | 0.02% | 1218442 SH | 2026年8月8日 | 每日 |
| IWM · iShares Trust | 0.01% | 3418265 SH | 2026年8月8日 | 每日 |
| FNDX · SCHWAB STRATEGIC TRUST | 0.01% | 1126552 NS | 2026年5月31日 | N-PORT |
| RSSL · Global X Funds | 0.01% | 56434 NS | 2026年4月30日 | N-PORT |
| FNDB · SCHWAB STRATEGIC TRUST | 0.01% | 53684 NS | 2026年5月31日 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 746733 SH | 2026年8月8日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.01% | 349881 SH | 2026年8月8日 | 每日 |
| DFAS · Dimensional ETF Trust | 0.01% | 466961 NS | 2026年4月30日 | N-PORT |
| ITWO · ProShares Trust | 0.01% | 6034 NS | 2026年5月31日 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.01% | 546576 NS | 2026年5月31日 | N-PORT |
| UWM · ProShares Trust | 0.01% | 4719 NS | 2026年5月31日 | N-PORT |
| URTY · ProShares Trust | 0.00% | 4772 NS | 2026年5月31日 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.00% | 5006 NS | 2026年5月31日 | N-PORT |
| HDG · ProShares Trust | 0.00% | 120 NS | 2026年5月31日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 202789 NS | 2026年4月30日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 33838 NS | 2026年4月30日 | N-PORT |
| ITOT · iShares Trust | 0.00% | 203866 SH | 2026年8月8日 | 每日 |
| IWV · iShares Trust | 0.00% | 41727 SH | 2026年8月8日 | 每日 |
| DCOR · Dimensional ETF Trust | 0.00% | 6184 NS | 2026年4月30日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 31135 NS | 2026年4月30日 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0.00% | 70316 NS | 2026年5月31日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 1347195 SH | 2026年8月8日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 3813888 SH | 2026年8月8日 | 每日 |
| VPLS · VANGUARD MALVERN FUNDS | 0.00% | 20000 PA | 2026年8月8日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 9817 SH | 2026年8月8日 | 每日 |
| DFSU · Dimensional ETF Trust | 0.00% | 24 NS | 2026年4月30日 | N-PORT |